WE@Yale Women Innovators Series: Cami Samuels

The WE@Yale Women Innovators speaker series is designed to foster community discussion, idea sharing, and best practices in support of Yale women and non-binary femme entrepreneurs and innovators. Community members of all genders are welcome to attend these talks, which are free and open to the public.

Cami Samuels focuses on healthcare with an emphasis on biotech, medical devices, and consumer health. She currently serves on the board of Iris, Unity (UBX), and XCaliber – and previously served on the board of several other Venrock companies including Corvidia (sold to Novo Nordisk), Spirox (acquired by Stryker via Entellus) and RegenXBIO (RGNX). Prior to Venrock, Cami was a Managing Director at Versant Ventures where she supported many companies including Genomic Health (GHDX), Jazz (JAZZ), Kythera (KYTH/acq by Allergan), Novacardia (acq by Merck), and ParAllele (acq by Affymetrix). Before her venture career, Cami worked in business development at Tularik (acq by Amgen).

During her early career, Cami worked in corporate development at Genzyme and Millennium Predictive Medicine and was a management consultant at LEK Consulting. Cami earned her Bachelor’s degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar..

This event will take place online; a Zoom link will be provided to registered attendees.

WE@Yale is a partnership between the Tsai Center for Innovative Thinking at Yale (Tsai CITY) and the Yale SOM Program on Entrepreneurship.